Targeting by PG545 enhances PARP inhibitor response in ovarian cancer

A new therapeutic strategy to sensitize ovarian cancer cells to poly (ADP-ribose) polymerase inhibitors by the drug PG545 (Pixatimod) analyzed using patient-derived ascites samples and preclinical mouse models of ovarian cancer.
Targeting by PG545 enhances PARP inhibitor response in ovarian cancer

Ovarian cancer and its treatment limitations:

Despite recent advances in understanding the biology of high-grade serous ovarian cancer (HGSOC), surgical debulking and platinum-based chemotherapy remain the standard of care. Over 80% of cases experience recurrence, with approximately 12,000 patients succumbing to ovarian cancer annually in the United States [1]. Targeted therapies for common genetic alterations in HGSOC, such as poly (ADP-ribose) polymerase inhibitors (PARPis), have gained FDA approval for both frontline and recurrent use [2]. However, while PARPi therapy extends median progression-free survival for ovarian cancer patients with homologous recombination repair (HRR) deficiency, numerous mechanisms of PARPi resistance have been reported. Therefore, PARPi resistance is an emerging therapeutic challenge, necessitating the development of strategies to sensitize cancer cells to PARPis.

Background of the study:

 PG545 (Pixatimod), a highly sulfated small molecule compound, was designed with a core heparan sulfate mimetic structure to target heparanase and heparin binding growth factor (HB-GF) signaling [3]. Recently studied in a Phase 1a monotherapy trial for patients with advanced solid tumors (NCT02042781), PG545 is known for its anti-cancer activity in various pre-clinical cancer models, including ovarian, endometrial, pancreatic, colon, breast, and lung cancers [4-7]. Previous research indicated that PG545 inhibits growth factor-mediated signaling in ovarian cancer to enhance chemotherapy response [4]. Heparan sulfate proteoglycans (HSPGs) in addition to its role in signaling, are also involved in endocytosis of molecules like the oncoprotein DEK [8]. Upregulated in several cancer types, DEK, functions as a DNA repair protein in the nucleus, regulating the HRR pathway [9-10]. Secreted DEK acts as a chemoattractant for inflammatory cells and regulates inflammation in the tumor microenvironment [11]. PG545 inhibits HSPG-mediated endocytosis of DEK, impacting its repair function [12]. Overexpression of DEK in ovarian cancer is linked to cell growth, DNA damage, and increased chemotherapy sensitivity [13].

Key findings:

In our study, we discovered that PG545 induces DNA damage in ovarian cancer cells, a previously uncharacterized effect. We aimed to investigate the mechanisms and outcomes of this effect. PG545 causes DNA single- and double-strand breaks, reduces the expression of RAD51 (a crucial DNA repair protein), and inhibits the HRR pathway in cancer cells through autophagy. Additionally, PG545 prevents internalization of the DEK oncoprotein by cancer cells. Since DEK relies on heparan sulfate binding for function, PG545 disrupts HSPG-mediated endocytosis, leading to loss of nuclear DEK and inhibition of the DNA repair pathway. PG545 synergizes with PARPis in ovarian cancer cell lines in vitro, including those resistant to PARPi monotherapy. This synergy was observed in 55% of primary cultures of patient-derived ascites samples in an ex vivo model. Furthermore, the combination of PG545 and the PARPi rucaparib induced increased DNA damage and reduced tumor burden in mice with HRR-proficient OVCAR5 cell line xenografts, compared to monotherapy, in an in vivo setting. The combination also demonstrated synergistic anti-tumor activity in an immunocompetent syngeneic ID8F3 ascites model in vivo. These findings suggest that targeting the tumor microenvironment's signaling, specifically the DEK-HSPG interaction, using PG545, might inhibit DNA repair and sensitize cells to PARPi treatment.

Take-home message and future directions:

This study presents the first report on PG545's role in inducing the DNA damage pathway in cancer cells. It introduces a novel therapeutic strategy—using PG545 to sensitize ovarian cancer cells to PARPi treatment. This strategy is supported by results from patient-derived ascites samples, ex vivo and in vivo preclinical models of ovarian cancer, and in vitro ovarian cancer cell lines. Notably, HR deficiency isn't essential for the observed synergy, as PG545/PARPi synergy was seen in both HR-deficient and PARPi-resistant lines. The ability of PG545 to downregulate RAD51 via autophagy in HR-proficient cell lines adds to PARPi sensitization, warranting further preclinical investigation. Mechanistically, PG545 inhibits DEK internalization and its function as a DNA repair protein, inducing DNA damage and sensitizing cells to PARPis. To progress, additional ex vivo studies with patient-derived ascites samples are needed to correlate treatment responses with clinical characteristics or mutational statuses. Future work utilizing patient-derived xenograft models will further evaluate the combination treatment's efficacy, especially in preclinical models resistant to current therapies, with hopes of identifying additional treatment-selection biomarkers.


  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33
  2. Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clin Cancer Res 2017;23:4095-106
  3. Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs 2010;28:276-83
  4. Winterhoff B, Freyer L, Hammond E, Giri S, Mondal S, Roy D, et al. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur J Cancer 2015;51:879-92
  5. Jung DB, Yun M, Kim EO, Kim J, Kim B, Jung JH, et al. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. Oncotarget 2015;6:4992-5004
  6. Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, et al. A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. Br J Cancer 2018;118:1035-41
  7. Hoffmann R, Sarkar Bhattacharya S, Roy D, Winterhoff B, Schmidmaier R, Dredge K, et al. Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer. Biochem Pharmacol 2020;178:114003
  8. Christianson HC, Belting M. Heparan sulfate proteoglycan as a cell-surface endocytosis receptor. Matrix Biol 2014;35:51-5
  9. Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, et al. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res 2011;39:7465-76
  10. Smith EA, Gole B, Willis NA, Soria R, Starnes LM, Krumpelbeck EF, et al. DEK is required for homologous recombination repair of DNA breaks. Sci Rep 2017;7:44662
  11. Saha AK, Kappes F, Mundade A, Deutzmann A, Rosmarin DM, Legendre M, et al. Intercellular trafficking of the nuclear oncoprotein DEK. Proc Natl Acad Sci U S A 2013;110:6847-52
  12. Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M, Khodadoust MS, et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006;26:9484-96
  13. Hacker KE, Bolland DE, Tan L, Saha AK, Niknafs YS, Markovitz DM, et al. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival. Neoplasia 2018;20:1209-18

Please sign in or register for FREE

If you are a registered user on Cancer Community, please sign in